

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vincent Medical Holdings Limited

永勝醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1612)

**VOLUNTARY ANNOUNCEMENT
APPROVAL FROM THE NMPA
FOR THE O₂FLO RESPIRATORY UNIT**

This announcement is made by Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis with the purpose of allowing the investing public to understand the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medical device or treatment.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 17 February 2020, the Group received approval from the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (the “**PRC**”) for its respiratory humidification treatment device with model number of VUN-001 (the “**O₂FLO Respiratory Unit**”) and the related accessories and disposables.

The O₂FLO Respiratory Unit, a non-invasive high flow oxygen therapy device, is used in the treatment of patients with chronic or acute respiratory distress such as pneumonia, viral pneumonia, chronic obstructive pulmonary disease, heart failure, and asthma. High flow oxygen therapy is a form of respiratory support where heated and humidified air is delivered to a patient at a high flow rate, it is clinically proven that the utilization of high flow oxygen therapy in appropriate patients can improve oxygenation, reduce the patient’s work of breathing and serve as a more economical, safer and easier alternative to invasive mechanical ventilation. The O₂FLO Respiratory Unit has received the approval from Japan’s Ministry of Health, Labour, and Welfare in August 2018 and Conformité Européenne (“**CE**”) Mark in November 2019, respectively. The Group is seeing positive sales in Japan and growing interest in CE approved countries.

The Group has received initial orders of the O₂FLO Respiratory Unit and related disposables from Hubei Province of the PRC. The Group believes that the device has good marketing potential and will enrich the Group's product line. Apart from the PRC, Japan and the European Union, the Group is also committed to registering and launching the device in the United States and other countries.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Vincent Medical Holdings Limited
Choi Man Shing
Chairman and Executive Director

Hong Kong, 19 February 2020

As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Mr. Guo Pengcheng as a non-executive Director, and Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.